On October 29, 2020, LianBio, a Chinese company focused on bringing paradigm-shifting medicines to patients in major Asian markets, announced it raised $310 million in an oversubscribed crossover financing. The financing was co-led by U.S. investors RA Capital and Venrock Healthcare Capital Partners, and Chinese investor CMG-SDIC Capital. Other leading specialist investors in the round included BlackRock, Casdin Capital, Farallon, Logos Capital, Perceptive Advisors, Pfizer Inc., Sphera Healthcare, T. Rowe Price Associates, Inc., Tybourne Capital Management, Vida Ventures, Viking Global Investors, and Wellington Management. Wilson Sonsini Goodrich & Rosati advised Tybourne Capital Management in the transaction.

The financing follows LianBio’s founding and initial financing provided by Perceptive Advisors. With the its global innovation mining platform validated by an impressive syndicate of investors, the company is poised to advance its business model in China and major Asian markets.

The Wilson Sonsini team advising Tybourne Capital Management includes Dan Koeppen and Kassandra Castillo.